These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1442 related articles for article (PubMed ID: 34866576)

  • 21. Causal effects of circulating lipids and lipid-lowering drugs on the risk of epilepsy: a two-sample Mendelian randomization study.
    Liang Z; Zhao L; Lou Y; Liu S
    QJM; 2023 Jun; 116(6):421-428. PubMed ID: 36964718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study.
    Ma W; Chen H; Zhang Z; Xiong Y
    PLoS One; 2024; 19(2):e0293960. PubMed ID: 38416763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of lipid-lowering drugs with risk of sarcopenia: a drug target mendelian randomization study and meta-analysis.
    Li J; Zang C; Lv H; Xiao Z; Li P; Xiao B; Zhou L
    Hum Genomics; 2024 Jul; 18(1):76. PubMed ID: 38961447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipids, lipid-modifying drug target genes and migraine: a Mendelian randomization study.
    Bi Y; Zhu Y; Tang S; Huang Y
    J Headache Pain; 2023 Aug; 24(1):112. PubMed ID: 37596566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mendelian randomization study of lipid metabolism characteristics and migraine risk.
    Hong P; Han L; Wan Y
    Eur J Pain; 2024 Jul; 28(6):978-986. PubMed ID: 38183343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating the effect of lipid-lowering agents on novel subtypes of adult-onset diabetes.
    Ye J; Guo K; Li J; Li X; Zhou Z; Yang L
    Diabetes Metab Res Rev; 2024 May; 40(4):e3793. PubMed ID: 38661109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.
    Sun L; Ding H; Jia Y; Shi M; Guo D; Yang P; Wang Y; Liu F; Zhang Y; Zhu Z
    Breast Cancer Res; 2022 Feb; 24(1):12. PubMed ID: 35151363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Target Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Atrial Fibrillation.
    Li F; Mei Y; Wu Q; Wu X
    Cardiology; 2024; 149(5):495-501. PubMed ID: 38531334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study.
    Li J; Yang Z; Wang T; Li M; Wu X; Fu X; Yang C; Li Y; Wang X; Lan Z; Li M; Chen S
    BMC Cancer; 2024 May; 24(1):667. PubMed ID: 38822303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
    Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
    Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study.
    Li Z; Tian M; Jia H; Li X; Liu Q; Zhou X; Li R; Dong H; Liu Y
    Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):197-206. PubMed ID: 37688479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid lowering and Alzheimer disease risk: A mendelian randomization study.
    Williams DM; Finan C; Schmidt AF; Burgess S; Hingorani AD
    Ann Neurol; 2020 Jan; 87(1):30-39. PubMed ID: 31714636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization Study.
    Dib MJ; Zagkos L; Meena D; Burgess S; Chirinos JA; Gill D
    Stroke; 2024 Jun; 55(6):1676-1679. PubMed ID: 38572634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study.
    Zhao SS; Yiu ZZN; Barton A; Bowes J
    JAMA Dermatol; 2023 Mar; 159(3):275-280. PubMed ID: 36696131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of lipid lowering drugs and the risk of systemic lupus erythematosus: a drug target Mendelian randomization.
    Wu T; Ye L; Wang S; Huang J; Zhang J
    Front Pharmacol; 2023; 14():1258018. PubMed ID: 37964871
    [No Abstract]   [Full Text] [Related]  

  • 36. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
    Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
    Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
    Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
    PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Causal effects of lipid-lowering drugs on inflammatory skin diseases: Evidence from drug target Mendelian randomisation.
    Zang C; Li J; Zhang Y; Deng W; Mao M; Zhu W; Chen W
    Exp Dermatol; 2024 Sep; 33(9):e15157. PubMed ID: 39227185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.
    Alghamdi J; Matou-Nasri S; Alghamdi F; Alghamdi S; Alfadhel M; Padmanabhan S
    Int J Neuropsychopharmacol; 2018 Dec; 21(12):1067-1075. PubMed ID: 29986042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating causal effects of atherogenic lipid-related traits on COVID-19 susceptibility and severity using a two-sample Mendelian randomization approach.
    Yoshikawa M; Asaba K; Nakayama T
    BMC Med Genomics; 2021 Nov; 14(1):269. PubMed ID: 34774031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 73.